Warfarin-associated hemorrhage and cerebral amyloid angiopathy: A genetic and pathologic study

Neurology

Volumn 55, Issue 7, 2000, Pages 947-951

  Rosand, Jonathan ^a   Hylek, Elaine M ^a   O'Donnell, Heather C ^a   Greenberg, Steven M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

AGED; ALLELE; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; CONTROLLED STUDY; FEMALE; GENETIC RISK; GENOTYPE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VASCULAR AMYLOIDOSIS;

EID: 0034633751     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.55.7.947     Document Type: Article

References (33)

1. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses
2. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective
3. Atrial fibrillation and stroke. Three new studies, three remaining questions
4. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation Stroke Prevention in Atrial Fibrillation II Study
5. Bleeding during antithrombotic therapy in patients with atrial fibrillation
6. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation Stroke Prevention in Atrial Fibrillation III randomised clinical trial
7. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin
8. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy
9. Risk factors for intracranial hemorrhage in outpatients taking warfarin
10. Hemorrhagic complications of anticoagulant treatment
11. Major bleeding during anticoagulation after cerebral ischemia: Patterns and risk factors. Stroke Prevention in Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups
12. Clinicopathologic studies of primary cerebral amyloid angiopathy
13. Cerebral amyloid angiopathy. A critical review
14. Fatal hemorrhage during anticoagulation of cardioembolic infarction: Role of cerebral amyloid angiopathy
15. Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: The Thrombolysis in Myocardial Infarction (TIMI) II pilot and randomized clinical trial combined experience
16. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology
17. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
18. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
19. Apolipoprotein E ε4 and cerebral hemorrhage associated with amyloid angiopathy
20. Apolipoprotein E-ε4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease
21. High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy
22. Association of apolipoprotein E ε2 and vasculopathy in cerebral amyloid angiopathy
23. Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy
24. High frequency of apolipoprotein E epsilon 2 allele is specific for patients with cerebral amyloid angiopathy-related haemorrhage
25. Case records of the Massachusetts General Hospital, case 22-1996
26. MRI detection of new hemorrhages: Potential marker of progression in cerebral amyloid angiopathy
27. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage
28. Cerebral amyloid angiopathy-related hemorrhage. Interaction of APOE ε2 with putative clinical risk factors
29. The apolipoprotein E ε2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage
30. ApoE genotype and survival from intracerebral haemorrhage
31. The apolipoprotein E ε4 allele and outcome in cerebrovascular disease
32. Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment
33. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation